Impact

From sales of medicines to impact on peoples’ lives, the Medicines Patent Pool’s work is a game-changer in the access to treatments space.

MPP in Numbers

0

patent holders with MPP signed agreements

0

generic manufacturers and product developers have sublicences from MPP

0

countries have benefitted from access to MPP-licensed products

0+

ongoing pharmaceutical development projects

0Bn

Billion dollars saved by the international community, from January 2012 to December 2019

0Bn

Billion doses of treatment supplied to date

0Mn

Million patient-years of treatment through MPP’s generic partners, from January 2012 to December 2019

KPMG calculated savings of USD1.44 billion and supply of 31.4 million patient-years of treatments through MPP’s generic partners from January 2012 to December 2019. Read the KPMG report.

Impact analysis, highlighting MPP’s sublicensees’ progress on treatments development, are available here.

IMPACT STORIES

After nearly 10 years of operations, the Medicines Patent Pool went to India to see first-hand how access to quality-assured generic medicines for HIV and hepatitis C has changed people’s life. In the first of our impact series videos, patients, medical experts, governments, among others, explain how MPP’s work has generated impact. From saving lives to increased access, originators, generic manufacturers and committed partners have worked with MPP to deliver the best quality treatments to those who need them most.

 

Below are stories and testimonies from people in some of the countries benefiting from these agreements, on how being able to access DTG has made a difference to them. Click here to read more.

Aibar Sultangaziev

Aibar Sultangaziev

Kyrgyzstan

“Almost everyone now wants dolutegravir, but we are trying to make this transition period gradual ... and people are very much looking forward to receiving TLD, the once-daily pill containing dolutegravir”

Read More

Luckyboy Mkhondwane

Luckyboy Mkhondwane

South Africa

“The improved quality of life experienced by dolutegravir-users, after the side effects of other treatment regimens, has been outstanding […]”

Read More

Anahit Harutyunyan

Anahit Harutyunyan

Armenia

“We will continue to monitor availability of DTG in Armenia […]. It is very important that we encourage the usage of these drugs as they solve the problem of adherence.”

Read More

George Kampango

George Kampango

Malawi

“In my community and through my advocacy work, it is clear that dolutegravir is able to change the lives of people living with HIV.”

Read More

MPP Logo

Subscribe to our Newsletter

Founded & funded by

Unitaid Logo

Other funders

This website uses cookies to ensure you get the best experience on our website. Learn More